Represented Small Pharma Ltd, a U.K.-based neuropharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, in its acquisition by Small Pharma Inc. (formerly Unilock Capital Corp.) (TSXV: DMT) by way of a qualifying transaction and its related brokered and non-brokered private placements for aggregate gross proceeds of $63 million and initial TSX Venture Exchange listing.
Represented Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, in the completion of a bought deal short form prospectus offering of units for aggregate gross proceeds of approximately $34 million.
Represented Cybin Inc. (the “Company”) (NEO: CYBN) in the completion of its reverse takeover of Clarmin Explorations Inc. pursuant to the terms of an amalgamation agreement among Cybin Corp., Clarmin and a wholly-owned subsidiary of the Company as well as a private placement offering of 60 million subscription receipts for aggregate gross proceeds of $45 million.
Represented Harborside Inc. (formerly Lineage Grow Company Ltd.) (CSE: HBOR) in the completion of its reverse takeover of FLRish, Inc. pursuant to the terms of a merger agreement among the Company, FLRish and Lineage Merger Sub Inc. by way of a “three-cornered merger.”
Represented Eve & Co Incorporated (TSXV: EVE) in the completion of a $10.45 million special warrant bought deal private placement.
Represented Eve & Co Incorporated (TSXV: EVE) in the completion of an $18.7 million construction facility with Royal Bank of Canada to fund the completion of a 780,000 sq. ft. expansion of its greenhouse production facility.